Palifermin
Title: Palifermin
CAS Registry Number: 162394-19-6
CAS Name: 24-163-Keratinocyte growth factor (human)
Additional Names: 24-163-fibroblast growth factor 7 (human); rHuKGF
Trademarks: Kepivance (Amgen)
Literature References: Recombinant epithelial tissue growth factor of 141 amino acid residues; N-terminal truncated form of endogenous KGF. Mol wt approx 16.3 kDa. Prepn: D. J. Gospodarowicz, F. R. Masiarz, WO 9501434; eidem, US 5677278 (1995, 1997 both to Chiron). In vivo radioprotective effect: C. L. Farrell et al., Cancer Res. 58, 933 (1998). Clinical study in mucositis associated with myelosuppressive therapy: R. Spielberger et al., N. Engl. J. Med. 351, 2590 (2004). Review of therapeutic potential in oral mucositis: M. A. A. Siddiqui, K. Wellington, Drugs 65, 2139-2146 (2005); M. L. Radtke, J. M. Kolesar, J. Oncol. Pharm. Pract. 11, 121-125 (2005).
Therap-Cat: Radioprotective agent.
Keywords: Antineoplastic Adjunct; Radioprotective.

Others monographs:
Insulin GlulisineFlucloronideChlorothymol1,4-Bis(trichloromethyl)benzene
NitromersolPhosphorus TriselenideRiboflavinn-Dipropylamine
RhubarbBenzalkonium ChlorideButabarbital SodiumLead Borate
Thiolactic AcidRosuvastatinPhenoldisulfonic AcidNeovitamin A
©2016 DrugLead US FDA&EMEA